Immunology data shows inovio's ino-3107 induced expansion of new clonal t cells that infiltrate airway tissue and correspond with reduction of surgeries for rrp patients observed in phase 1/2 trial

New immunology data shows ino-3107 induced an expansion of new clonal t cells in blood that were not detectable prior to treatment new clonal t cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (rrp) caused by hpv-6 and hpv-11 data supporting mechanism of action for ino-3107 to be presented at 36th international papillomavirus conference in edinburgh, uk plymouth meeting, pa. , nov. 13, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, ino-3107, that was previously observed in a phase 1/2 trial of rrp patients.
INO Ratings Summary
INO Quant Ranking